January 31, 2019 ABERDEEN, Scotland–(BUSINESS WIRE)–SIRAKOSS Ltd, a developer of unique synthetic bone graft substitutes, announced today it has been granted CE Mark clearance in the European Union (EU) for Osteo3, a novel nanosynthetic bone graft substitute designed to improve patient healing, offering surgeons a more advanced solution for repairing bone fractures. Synthetic bone grafts …